Date of this Version
In a clinical trial where cattle were either given Excede® or not on arrival, ADG increased and F:G was numerically improved for cattle that received Excede compared to control cattle. There were no differences between initial or final BW, or DMI observed during the receiving period due to the administration of Excede. The incidence of bovine respiratory disease (BRD) for the 32 days of the study was 4.4% for cattle that received Excede at arrival and was different compared to the control cattle which was 12.2%. The correlation (-0.157) between DMI and morbidity observed in this study was not significant. Metaphylactic treatment with Excede improved ADG and effectively reduced the cumulative incidence of BRD during the study.